Funding | BEAM Alliance

Funding

This page is updated thanks to the FFund team; if any question, please contact Lorina Gjonaj, Senior Consultant – M +316 347 340 00 | lorina.gjonai@ffund.nl or Maarten Korving, Consultant, M +316 393 425 26 | maarten.korving@ffund.nl.


General non-dilutive instruments


Eurostars-3

Eurostars is a joint programme between EUREKA and the European Commission, co-funded from the national budgets of 36 Eurostars Participating States and Partner Countries and by the European Union. It aims to bring increased value to the economy, higher growth and more job opportunities. Eurostars supports international innovative projects led by research and development- performing small- and medium-sized enterprises (R&D-performing SMEs). With its bottom-up approach, Eurostars supports the development of rapidly marketable innovative products, processes and services that help improve the daily lives of people around the world. Eurostars has been carefully developed to meet the specific needs of SMEs. It is an ideal first step in international cooperation, enabling small businesses to combine and share expertise and benefit from working beyond national borders.

Funding Name: Eurostars
Funding Organization: Eureka
Amount of funding per project: €500K per partner (varies per country)
Funding versus total project costs: 35-45% of total project costs (varies per country)
Funding type: Subsidy
Close date: 2 deadlines/year (Feb 4th 2021, Sept 2021 – specific date still unknown)
Duration of eligible projects: 36 months
Evaluation results expected: December 2021

Scope and Eligibility criteria:
– Programme supporting R&D performing SMEs and their partners
– The development of new products, processes, and services
– The budget (excluding subcontracting) of the R&D-performing SME is equal to at least 50.00% of the total project budget
– At least 2 different partners from 2 different Eurostars countries
– No organization can be responsible for more than 75% of the total project budget.
– No participants from a given country may be responsible for more than 75% of the total project budget
– The project must be completed in 36M or fewer and the market introduction (or the start of clinical trials for life sciences projects) is planned to occur within 24M of the project’s completion
– Two application submission deadlines annually
To qualify as an R&D-performing SME, an organization must first comply with the EC definition of an SME. In addition, it must also meet the thresholds for dedicated R&D FTEs or turnover set by EUREKA.This and all other eligibility criteria are described in detail in the Guidelines. An explanation of the eligibility criteria imposed by the programme and the method of calculation are provided in detail in the Eligibility Guidelines.

Procedure and application process: For more information click here.


EIC Accelerator

The EIC Accelerator supports high-risk, high-potential small and medium-sized enterprises and innovators to help them develop and bring onto the market new innovative products, services and business models that could drive economic growth. Selected companies receive funding and optional equity, and are offered business coaching and mentoring services to scale up their innovation idea. In addition, they receive acceleration services to connect with investors, corporates and likeminded entrepreneurs.

Funding Name: EIC Accelerator
Funding Organization: European Commission
Amount of funding per project: € 0.5-2.5M (+€0.5-15M equity)
Funding versus total project costs: 70% of eligible costs (grant part)
Close date: 2 deadlines/year (upcoming call: October 6th 2021)
Duration of eligible projects: 12-24 months (maximum)
Evaluation results expected: 3-6 weeks later (for 2nd and 3rd phase)

Scope: The EIC Accelerator helps you develop your business concept further into a market-ready product, service or process aligned with your company’s growth strategy. Activities could, for example, include trials, prototyping, validation, demonstration and testing in real-world conditions, and market replication. If the activity concerns a primarily technological innovation, a Technology Readiness Level (TRL) of 6-8 is envisaged for projects requesting grants-only. Projects are able to receive between € 0.5 and € 2.5 million in the form of grants. They can request a higher or lower amount when applying if justified accordingly. Projects should normally take 12 to 24 months to complete but could be longer in exceptional and well-justified cases. Since 5 June 2019 the EIC Accelerator offers blended finance in the form of an optional investment in equity in addition to the grant, to single for-profit SMEs. Grants will finance activities from TRL 6-8. Activities above TRL 8 will be funded through equity. The equity part is optionable when applying for the EIC Accelerator. The maximum of investment in the form of equity is € 15 million.

Eligibility criteria: The EIC Accelerator is designed for small and medium-sized enterprises (SMES) with radically new ideas underpinned by a business plan for rolling out marketable innovation solutions and with ambitions to scale up. It targets for-profit SMEs only, including young companies and start-ups, from any sector – there are no set topics. Since 5 June 2019 only single companies (as opposed to consortia) can apply for EIC Accelerator.Companies that apply must be established in an EU Member State or a Horizon 2020 associated country. Large corporates, research centers or scientists cannot apply directly but they can participate in projects as subcontractors or third parties and don’t need to be established in an EU Member State or associated country.

Procedure and application process: For more information on procedures click here.


HORIZON-HLTH-2022-DISEASE-06-03

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden” of Europe Horizon. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:
– The scientific and clinical communities use the increased knowledge on pathogens and better understanding of the immune system’s role in infectious diseases to develop vaccines with improved efficacy.
– Vaccine manufacturers use more innovative and sustainable manufacturing technologies and improved GMP manufacturing know-how for producing the next generation of vaccines.
– A diversified portfolio of vaccine candidates ready for testing in clinical trials help policy makers and funders to make informed decisions about support to vaccine development.

Funding Name: Vaccines 2.0 – developing the next generation of vaccines
Funding Organization: European Commission
Amount of funding per project: € 8M (Total budget 40M)
Funding versus total project costs: Unspecified
Close date: Feb 1st, 2022 (First Stage) / Sep 6th, 2022 (Second stage)
Duration of eligible projects: Typically 4-5 years
Evaluation results expected: Typically 5 months

Scope: Infectious diseases, including antimicrobial resistant (AMR) infections, remain a major threat to health and health security in the EU and globally. The availability of more effective, accessible and affordable vaccines would provide the most cost-effective preventive measure against the health threat of epidemics and AMR pathogens. Vaccines against diseases, such as AIDS, tuberculosis (TB), malaria, neglected tropical diseases, hepatitis C and water-borne diseases are essential to achieve the WHO targets to control the spread of infectious diseases. The first generation of vaccines against some of the pathogens have proven to be suboptimal and not effective enough to protect the population. Many viruses of pandemic potential are variable in their surface antigen composition, and novel technologies are required to develop efficient vaccines against each new variant efficiently and in a short timeframe. To ensure that more effective, accessible and affordable vaccines against all major infectious diseases become a reality, it is essential to sustain a diverse and modernised vaccine development pipeline.

Eligibility criteria:
• Innovation and integration of expertise and capabilities, including alignment of preclinical and clinical models, biomarker studies and new vaccine approaches from discovery to late-stage development, from bench-based research to clinical development of promising preventive candidates.
• Application of iterative processes (including cross-learning, back-translation steps, integrative analysis of data) to allow exploitation and integration of novel findings between clinical, preclinical and discovery research and development.
• Deciphering mechanisms of protection of candidates, new approaches to antigen discovery and immunogen engineering, reverse vaccinology, evaluation of vaccines in novel platforms and technologies, novel adjuvants, innovative vaccine manufacturing approaches, relevant animal models, evaluation of alternative vaccine delivery routes.
• Effective, evidence-based decision-making for progression of vaccine candidates in the pipeline based on transparent and objective portfolio management. Regulatory requirements be considered. Sex, gender, age and socio-economic factors should be taken into account.

Procedure and application process: For more information on procedures click here.


HORIZON-HLTH-2021-DISEASE-04-05

There is the need to move towards the integration of the various disciplines to overcome this fragmentation, thus tackling the problem of AMR with a comprehensive One Health approach bringing the diverse actors together. Importantly, better co-ordination is essential to foster and accelerate the development and adoption of solutions to reverse the rising levels of AMR.

Funding Name: A roadmap towards the creation of the European partnership on One Health antimicrobial resistance (OH AMR)
Funding Organization: European Commission
Amount of funding per project: € 500k (Total budget €500k)
Funding versus total project costs: 100%
Close date: Sep 21st, 2021
Duration of eligible projects: Unspecified
Evaluation results expected: Typically 5 months

Scope: Proposals should cover all of the following activities:
Development of a Strategic Research and Innovation Agenda (SRIA) for a comprehensive approach to inform the expected future European partnership on One Health antimicrobial resistance (OH AMR).
Robust communication and effective information exchange between diverse scientific disciplines and among multiple sectors of the society that are implicated such as patients, clinicians, veterinarians, pharmacists, food producers, pharmaceutical industry, policy makers and researchers (including those working in the social sciences and humanities).
• As regards integration and coordination activities, the proposal should be ambitious in its inclusiveness, encompassing the broad spectrum of pathogens, and mobilise experts from diverse disciplines, including from the social sciences and humanities, to address understanding, prevention, monitoring, epidemiology (e.g. emergence, spread, persistence), treatments and detection of AMR.

Expected Outcome:
1. Research funders, policy makers and the research community have a Strategic Research and Innovation Agenda (SRIA) to be implemented by the expected future European partnership on One Health antimicrobial resistance (OH AMR).
2. Research funders, policy makers and the research community profit from a strengthened coordination and collaboration among different fields of research and innovation with relevance to antimicrobial resistance (AMR) maintaining Europe’s leading role in combating AMR.
3. Academics, innovators, end-users, researchers, public health authorities and citizens form a strong ecosystem that improves the implementation of the European One Health AMR strategy and its contribution to the Sustainable Development Goals.
4. Research funders, policy makers and the research community are in a position to close the current gaps and break existing silos on AMR in accordance with the European One Health Action Plan against AMR102.

Procedure and application process: For more information on procedures click here.


HORIZON-HLTH-2021-IND-07-02

The aim of this topic is to prepare for the establishment of a pull incentive for new antimicrobials where there is an unmet public health need and a market failure. Proposers are expected to create the conditions for the establishment of a future innovation partnership. With the help of experts, potential procurers of new antimicrobials in the Member States have to set out the requirements and conditions for the final product(s) to be developed and purchased. This will needs to be guided by public health needs and should be based on priority pathogens such as those identified by WHO. These requirements and conditions needed to guide development will have to be developed with input of scientific experts and in close collaboration with Commission services, and need to be agreed upon with a view of EU Member States’ and Associated States commitments to purchase the new antimicrobials. Proposers should also develop a broad communication strategy towards stakeholders and other potential procurers.

Funding Name: Development, procurement and responsible management of new antimicrobials
Funding Organization: European Commission
Amount of funding per project: € 2M (Total budget €2M)
Funding versus total project costs: 100%
Close date: Sep 21st, 2021
Duration of eligible projects: Unspecified
Evaluation results expected: Typically 5 months 

Scope: Proposals are expected to address all of the following:
• Emerging health threats, particularly those resulting from antimicrobial resistance (AMR), and identification of relevant public health needs in the development of new antibiotics.
• Design of a feasible option for a pull incentive that combines EU support for late stage development of antimicrobials with procurement by Member States and Associated Countries (implementation of the pull incentive will be beyond the scope of this CSA).
• Readiness and interest of potential developers/suppliers of antimicrobials
• Market failures and the challenges of availability and accessibility of therapeutics.
• Conditions for development and purchase of new antimicrobials.
• Requirements for financing.
• Conditions for prudent use of new antimicrobials.

Expected Outcome:
Proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:
1. Health authorities and healthcare providers have identified the needs and potential procurers;
2. Potential procurers are ready to establishing an innovation partnership for the development and the procurement of new antimicrobials;
3. Potential procurers are able to engage and commit financially in view of the establishment of an innovation partnership.

Procedure and application process: For more information on procedures click here.


Long-term engaging institutions and programmes


barda

Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response, was established to aid in securing our nation from chemical, biological, radiological, and nuclear (CBRN) threats, as well as from pandemic influenza (PI) and emerging infectious diseases (EID). BARDA supports the transition of medical countermeasures such as vaccines, drugs, and diagnostics from research through advanced development towards consideration for approval by the FDA and inclusion into the Strategic National Stockpile.BARDA will draw on its extensive experience of successfully advancing promising medical countermeasures through late-stage development and provide $30 million during the project’s first year and up to $250 million during the five-year program.

Funding Name: Broad Agency Announcement (BAA)
Funding Organization: BARDA
Amount of funding per project: € No maximum
Funding versus total project costs: 100%
Close date: None
Duration of eligible projects: Up to 5 years
Evaluation results expected: Unspecified 

Scope: Due to the COVID-19 response, any white papers or full proposal submissions, other than those that are in support of COVID-19, will be put into a queue. Once the response to COVID-19 has subsided, we will resume normal review of submissions for other research areas of interest. BARDA will not be able to meet the timelines highlighted in the Broad Agency Announcement.
COVID-19 response related Areas of Interest includes:
• AOI 7.7.1 Diagnostic Assay for Human Coronaviruses
• AOI 7.7.2 Diagnostic Assay for Detection of SARS-CoV-2 Virus
• AOI 7.7.3 Diagnostic Assay for Detection of COVID-19 Neutralizing Antibodies
• AOI 7.7.5 Screening Tests at Point of Care (2-minute Time to Result)
• AOI 9.2 COVID-19 Therapeutics
• AOI 17 Advanced Manufacturing Technologies

Eligibility:
Applicants can be from any country.
Applicants may include single entities or teams from private sector organizations, government laboratories, and academic institutions.

Procedure and application process: For more information click here.


carb-x

Co-founded by BARDA, CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is a global non-profit partnership funding new antibiotics, vaccines, rapid diagnostics, and other products to prevent, diagnose and treat life-threatening bacterial infections. CARB-X’s Global Accelerator Network provides business, scientific, and technical expertise to CARB-X-funded product developers to support their antibacterial research projects focused on the most serious drug-resistant bacteria identified by the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC).

Funding Name: CARB-X
Funding Organization: CARB-X
Amount of funding per project: Total budget €480M
Funding versus total project costs: Unspecified 
Close date: Unspecified
Duration of eligible projects: Unspecified 
Evaluation results expected: Unspecified 

Scope: The scope of CARB-X is to target drug-resistant bacteria highlighted on the ‘Antibiotic Resistant Threats in the United States’ report published by the CDC in 2013 or the Priority Bacterial Pathogens list published by the WHO in 2017 – with a priority on those pathogens deemed Serious or Urgent on the CDC list or Critical or High on the WHO list.

Eligibility:
There are currently no new funding rounds scheduled at the moment.

Procedure and application process: For more information click here.


InnovFin Infectious Diseases

The InnovFin Infectious Diseases Finance Facility (IDFF) provides financial products ranging from standard debt to equity-type financing for amounts typically between €7.5 million and €75 million, to innovative players active in developing innovative vaccines, drugs, medical and diagnostic devices or novel research infrastructures for combatting infectious diseases.

Funding Name: InnovFin Infectious Disease
Funding Organization: European Investment Bank
Amount of funding per project: €7.5-75M
Funding versus total project costs: Unspecified 
Close date: Unspecified
Duration of eligible projects: Unspecified 
Evaluation results expected: Unspecified 

Scope: Project costs may include clinical trial costs, set-up of commercialisation such as market access, development of prototypes or industrial roll-out of novel equipment, pre-clinical R&D costs and working capital requirement.
The product is being made available directly through the European Investment Bank.In addition, it should have passed successfully through the pre-clinical stage or through the proof-of-concept stage (in the case of medical and diagnostic devices). Funding can be invested in research infrastructure that provides facilities, resources and related services for use by the scientific community to conduct top-level research in the ID field.

Eligibility:
To be eligible for InnovFin Infectious Diseases Finance Facility (IDFF) funding, counterparties must comply with the following criteria:
The promoter should be a large pharmaceutical company, a mid-cap or a small and medium-sized enterprise (SME), a research institute/organisation, a university, a non-profit entity or a special-purpose vehicle (SPV). Promoters, sponsors and/or operators must be willing to substantially co-fund the project.

Procedure and application process: For more information click here.


CORNET fund

This CORNET Call for Proposals is based on existing funding programs for (collective) research in the participating countries/regions. As for the previous CORNET Calls, the added value is to make international collaboration possible for these national/regional programs, whereby every project participant will be funded by the funding organisation of their own country or region.

Funding Name: CORNET 32nd Call
Funding Organization: CORNET collective research networking
Amount of funding per project: Country-dependent (click here)
Funding versus total project costs: Unspecified 
Close date: Sep 29th, 2021
Duration of eligible projects: Max. 24 months 
Evaluation results expected: May 2022 

Scope: There is no thematic focus in the CORNET Calls for Proposals. Consortia from all industrial sectors are invited to submit proposals, dealing with any technology. However, some participating funding organizations might be interested to specifically support projects building in selected technical areas.

Eligibility:
The main eligibility criterion concerning submitted proposals is that they address Collective Research. The defining characteristics of Collective Research are:
• It serves the need of a wide grouping of companies, mostly small and medium sized enterprises (SMEs). This grouping is represented by a body such as an association, federation, a sectoral institute, an ad-hoc SME-grouping etc. (herein commonly referred to as ‘association’), which takes a key role in planning and organising the Collective Research work.
• Knowledge transfer (dissemination) is an integral part of Collective Research. It has to be ensured that the results of research are spread throughout the target grouping of companies by suitable measures (e. g. presentations, conferences, training etc.), and that there is a technical and legal path for technology transfer to all interested SMEs of the concerned sector, without discrimination. – Finally, Collective Research is pre-competitive meaning research and development in which there is collaboration but no competition.
A second essential criterion is to demonstrate clearly the significant added value, when performing the research on an international scale (more than just having a larger forum for the dissemination of individual results!). The project should be set up such that the specific competencies of the various countries or regions are combined to build up a level of knowledge and know-how, which could not be obtained by one single participant or by a set of individual participants working in parallel.

Procedure and application process: For more information click here.